Losartan

Uses

How it works

Benefits

Dosage & preparation

Highlighted claims

• Losartan is licensed for hypertension, renal failure with proteinuria, and cardiac failure. — Matrix-directed therapy losartan to identify the effect on the bone resorption marker carboxy-terminal crosslink of type I collagen telopeptide (CTX) in older adolescents and adults with osteogenesis imperfecta recruited from secondary care sites: the ‘MOI-A’ study; a randomised, phase 2/pilot, dose
• In the OIM mouse model, losartan reduced CTX by 40% and increased bone mass sixfold compared with placebo. — Matrix-directed therapy losartan to identify the effect on the bone resorption marker carboxy-terminal crosslink of type I collagen telopeptide (CTX) in older adolescents and adults with osteogenesis imperfecta recruited from secondary care sites: the ‘MOI-A’ study; a randomised, phase 2/pilot, dose
• Preclinical data indicate that losartan reduces circulating TGFβ, lowers bone turnover, and increases bone mass in osteogenesis imperfecta mice. — Matrix-directed therapy losartan to identify the effect on the bone resorption marker carboxy-terminal crosslink of type I collagen telopeptide (CTX) in older adolescents and adults with osteogenesis imperfecta recruited from secondary care sites: the ‘MOI-A’ study; a randomised, phase 2/pilot, dose
• The human-equivalent dose translation from mouse losartan studies is uncertain because one OIM mouse dose scales above the maximum human clinical dose. — Matrix-directed therapy losartan to identify the effect on the bone resorption marker carboxy-terminal crosslink of type I collagen telopeptide (CTX) in older adolescents and adults with osteogenesis imperfecta recruited from secondary care sites: the ‘MOI-A’ study; a randomised, phase 2/pilot, dose